Back to News
Market Impact: 0.2
Parabilis Begins Dose-Ranging Study For Zolucatetide In Treating FAP; Data By Q1 '27
Source: Nasdaq
Healthcare & Biotech
Parabilis Medicines (PBLS) reported initiation of a dose-ranging clinical study of Zolucatetide for familial adenomatous polyposis (FAP). The available article text provides no trial results, enrollment figures, or additional study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
PBLS0.45
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?